{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:27:17Z","timestamp":1779366437536,"version":"3.53.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008323","name":"Zanjan University of Medical Sciences","doi-asserted-by":"publisher","award":["1602001000"],"award-info":[{"award-number":["1602001000"]}],"id":[{"id":"10.13039\/501100008323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DR. ABIDI PHARMACEUTICALS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM). Most of the beneficial cardiovascular effects have been investigated in patients with heart failure and coronary artery disease (CAD). Yet, few human studies have been conducted to investigate the molecular mechanisms underlying these clinically beneficial effects in patients with CAD. Accordingly, the EMPA-CARD trial was designed to focus on the molecular effects of empagliflozin in patients with T2DM and CAD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this multicenter, triple-blind randomized controlled trial, patients with documented known T2DM and CAD will be recruited. They will be randomized on a 1:1 ratio and assigned into two groups of empagliflozin 10\u00a0mg\/daily and placebo. The primary endpoint is the effect of empagliflozin on changes of plasma interleukin 6 (IL-6) after 26\u00a0weeks of treatment. The secondary endpoints will consist of changes in other inflammatory biomarkers (Interleukin 1-beta and high-sensitive C-reactive protein), markers of oxidative stress, platelet function, and glycemic status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The EMPA-CARD trial mainly tests the hypothesis that SGLT2 inhibition by empagliflozin may improve inflammatory status measured as reduction in inflammatory biomarkers in patients with T2DM and CAD. The results will provide information about the underlying mechanisms of SGLT2 inhibition that mediate the beneficial effects of this medication on clinical outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>\n                           <jats:italic>Trial registration<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>Iranian Registry of Clinical Trials. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.IRCT.ir\">www.IRCT.ir<\/jats:ext-link>, Identifier: IRCT20190412043247N2. Registration Date: 6\/13\/2020. Registration timing: prospective.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-021-02131-1","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:02:55Z","timestamp":1625040175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Study rationale and design of a study of EMPAgliflozin\u2019s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Sepehr","family":"Gohari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Reshadmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Khodabandehloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-1188","authenticated-orcid":false,"given":"Hassan","family":"Ahangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Arsang-Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samin","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Dadashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Javad","family":"Muhammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Gohari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"2","key":"2131_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.freeradbiomed.2005.06.018","volume":"40","author":"D Jay","year":"2006","unstructured":"Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med. 2006;40(2):183\u201392.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"2131_CR2","doi-asserted-by":"publisher","first-page":"850","DOI":"10.4239\/wjd.v6.i6.850","volume":"6","author":"AT Kharroubi","year":"2015","unstructured":"Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. World J Diabetes. 2015;6(6):850\u201367.","journal-title":"World J Diabetes"},{"issue":"12","key":"2131_CR3","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jdiacomp.2017.08.005","volume":"31","author":"E Gourgari","year":"2017","unstructured":"Gourgari E, Wilhelm EE, Hassanzadeh H, Aroda VR, Shoulson I. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. J Diabetes Complicat. 2017;31(12):1719\u201327.","journal-title":"J Diabetes Complicat"},{"issue":"24","key":"2131_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u2013mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459\u2013502.","journal-title":"Circulation"},{"issue":"9933","key":"2131_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/S0140-6736(14)60613-9","volume":"383","author":"SH Ley","year":"2014","unstructured":"Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014;383(9933):1999\u20132007.","journal-title":"Lancet"},{"issue":"3","key":"2131_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1742-1241.2010.02544.x","volume":"65","author":"C Bailey","year":"2011","unstructured":"Bailey C, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65(3):314\u201322.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"2131_CR7","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1124\/jpet.114.213454","volume":"350","author":"HH Hansen","year":"2014","unstructured":"Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, Mark M, et al. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves \u03b2-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther. 2014;350(3):657\u201364.","journal-title":"J Pharmacol Exp Ther"},{"issue":"22","key":"2131_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"2131_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","volume":"5","author":"DZ Cherney","year":"2017","unstructured":"Cherney DZ, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2131_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333\u20139.","journal-title":"Diabetologia"},{"key":"2131_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijcard.2017.03.089","volume":"241","author":"P Perrone-Filardi","year":"2017","unstructured":"Perrone-Filardi P, Avogaro A, Bonora E, Colivicchi F, Fioretto P, Maggioni AP, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017;241:450\u20136.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2131_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/XCE.0000000000000141","volume":"7","author":"G Rodriguez-Araujo","year":"2018","unstructured":"Rodriguez-Araujo G, Nakagami H. Pathophysiology of cardiovascular disease in diabetes mellitus. Cardiovasc Endocrinol Metab. 2018;7(1):4\u20139.","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"11","key":"2131_CR13","doi-asserted-by":"publisher","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, Kr\u00f6ller-Sch\u00f6n S, Welschof P, Jansen T, Hausding M, Mikhed Y, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9(11):e112394.","journal-title":"PLoS One."},{"issue":"11 Supplement","key":"2131_CR14","doi-asserted-by":"publisher","first-page":"A1852","DOI":"10.1016\/S0735-1097(18)32393-3","volume":"71","author":"CG Santos-Gallego","year":"2018","unstructured":"Santos-Gallego CG, Zafar M, San Antonio R, Ibanez JAR, Botija MBP, Ishikawa K, et al. The SGLT2 inhibitor empagliflozin does not exhibit pro thrombotic effects. J Am Coll Cardiol. 2018;71(11 Supplement):A1852.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2131_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57(4):660\u201371.","journal-title":"Diabetologia"},{"key":"2131_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.redox.2018.09.025","volume":"20","author":"T Yuan","year":"2019","unstructured":"Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247\u201360.","journal-title":"Redox Biol"},{"issue":"5","key":"2131_CR17","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2337\/dc18-1569","volume":"42","author":"A Latva-Rasku","year":"2019","unstructured":"Latva-Rasku A, Honka M-J, Kullberg J, Mononen N, Lehtim\u00e4ki T, Saltevo J, et al. The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients. Diabetes Care. 2019;42(5):931\u20137.","journal-title":"Diabetes Care"},{"issue":"2","key":"2131_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1586\/erp.11.9","volume":"11","author":"MT King","year":"2011","unstructured":"King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(2):171\u201384.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"10254","key":"2131_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329.","journal-title":"Lancet"},{"issue":"21","key":"2131_CR20","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"issue":"1","key":"2131_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"S Gupta","year":"2017","unstructured":"Gupta S, Maratha A, Siednienko J, Natarajan A, Gajanayake T, Hoashi S, et al. Analysis of inflammatory cytokine and TLR expression levels in type 2 diabetes with complications. Sci Rep. 2017;7(1):1\u201310.","journal-title":"Sci Rep"},{"issue":"11S","key":"2131_CR22","doi-asserted-by":"publisher","first-page":"A1830-A","DOI":"10.1016\/S0735-1097(18)32371-4","volume":"71","author":"SA Tan","year":"2018","unstructured":"Tan SA, Tan L. Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-\u039b, tumor necrosis factor-\u0391, interleukin-6: possible mechanism of decreasing cardiovascular risk in diabetes mellitus. J Am Coll Cardiol. 2018;71(11S):A1830-A.","journal-title":"J Am Coll Cardiol"},{"issue":"S1","key":"2131_CR23","doi-asserted-by":"publisher","first-page":"1148-P","DOI":"10.2337\/db20-1148-P","volume":"69","author":"M Janic","year":"2020","unstructured":"Janic M, Lunder M, Sabovic M, Janez A. Antioxidative effects of empagliflozin and metformin in type 1 diabetes mellitus patients. Am Diabetes Assoc. 2020;69(S1):1148-P.","journal-title":"Am Diabetes Assoc"},{"issue":"1","key":"2131_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-016-0473-7","volume":"15","author":"H Kusaka","year":"2016","unstructured":"Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016;15(1):1\u201314.","journal-title":"Cardiovasc Diabetol"},{"issue":"1\u20133","key":"2131_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","volume":"715","author":"A Tahara","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1\u20133):246\u201355.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"2131_CR26","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.2337\/db17-1280","volume":"67","author":"MR Marasco","year":"2018","unstructured":"Marasco MR, Conteh AM, Reissaus CA, Cupit JE, Appleman EM, Mirmira RG, et al. Interleukin-6 reduces \u03b2-cell oxidative stress by linking autophagy with the antioxidant response. Diabetes. 2018;67(8):1576\u201388.","journal-title":"Diabetes"},{"issue":"15","key":"2131_CR27","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1111\/bph.12713","volume":"171","author":"D Qu","year":"2014","unstructured":"Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol. 2014;171(15):3595\u2013603.","journal-title":"Br J Pharmacol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02131-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:05:59Z","timestamp":1625040359000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02131-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2131"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02131-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"21 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The EMPA-CARD trial is conducting in accordance with the principles of the declaration of Helsinki and all subsequent revisions. The study was approved by the ethics committee of Zanjan university of Medical Sciences. All patients provided with written informed consent prior to the recruitment. Moreover, the study protocol was prospectively registered on the Iranian Registry of Clinical Trials (, Identifier: IRCT20190412043247N2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors contributing to the study have nothing relevant to disclose. Only the study authors are responsible for conducting and reporting the final contents of the trial. This study has received a non-financial funding from the Dr. Abidi Pharmaceutical Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}